Siga Technologies approved in Japan for treatment of orthopoxviruses

Siga Technologies (SIGA)’ antiviral treatment Tepoxx, has received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, as well as complications following smallpox vaccination in adults and pediatric patients weighing at least 13 kg. Tepoxx is the first antiviral therapy approved by the Pharmaceuticals and Medical Devices Agency, in collaboration with the Japan Ministry of Health, Labour and Welfare, for the treatment of orthopoxviruses. In partnership with Japan Biotechno Pharma, Siga’s exclusive distributor in Japan, Siga has delivered an order of Tepoxx to help build Japan’s strategic national stockpile. Tpoxx is approved in the U.S. and Canada for the treatment of smallpox. In the E.U. and U.K., marketed as Tecovirimat-SIGA, it is approved for the treatment of smallpox, mpox, cowpox, and to treat complications following smallpox vaccination.